-

01:20:41 AM

SONN Stock News

SONN - Sonnet BioTherapeutics Holdings Inc

02/01/23 8:00 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

SON-1210 elicited no serious adverse events in repeat, subcutaneous dosing in a GLP toxicology study SON-1210 was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose level Data show controlled induction of IFNg with no signs of cytokine release

RHEA-AI

neutral

01/19/23 8:00 AM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010

24 healthy volunteers have been dosed in study SB102 to assess the safety, PK, and PD of SON-1010 without the background of prior chemotherapy PK data shows an extended half-life of SON-1010 of approximately 112 hours, compared to 12 hours for rhIL-12 Simulation of the controlled and prolonged

RHEA-AI

neutral

01/09/23 8:00 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer

Sonnet's lead product, SON-1010, to be evaluated in combination with Roche's atezolizumab (Tecentriq ®) Sonnet will sponsor the clinical study in patients with platinum-resistant ovarian cancer, scheduled to commence during the second calendar quarter of 2023, and Roche will supply atezolizumab

RHEA-AI

positive

12/15/22 4:05 PM

Nasdaq : SONN

earningslow float

Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30 th, 2022 and

RHEA-AI

positive

11/02/22 8:00 AM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010

The SB101 and SB102 studies have together dosed 36 subjects to date as dose escalation continues Cytokine data show extended pharmacokinetics of SON-1010 with controlled induction of IFNγ and no signs of cytokine release syndrome All but one patient remain on study, with evidence of tumor

RHEA-AI

neutral

11/01/22 4:05 PM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010

RHEA-AI

neutral

10/31/22 7:30 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates

RHEA-AI

very positive

10/04/22 8:00 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet BioTherapeutics"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on

RHEA-AI

neutral

09/26/22 8:00 AM

Nasdaq : SONN

managementlow float

Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC) The BAC will advise the company on business

RHEA-AI

very positive

09/21/22 8:00 AM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

RHEA-AI

very positive

SONN Data

IndustryFood Service Contractors
Websitesonnetbio.com
CeoMichael Pruitt
Security nameSonnet BioTherapeutics Holdings Inc
Issue typecs
SectorAccommodation and Food Services
Sic code5812
Employees9
Tags
- Consumer Services
- Restaurants
- Health Technology
- Biotechnology
- Accommodation and Food Services
- Food Service Contractors
Address100 Overlook Center
Address2Suite 102
StateNew Jersey
CityPrinceton
Zip08540
CountryUS
Phone16093752227

About Sonnet BioTherapeutics Holdings Inc

Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and 'hitch-hikes' on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.